Lasker∼Koshland to Genetics Pioneer  by Botstein, David
Leading Edge
BenchMarksLaskerKoshland to Genetics Pioneer
David Botstein1,*
1Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA
*Correspondence: botstein@calicolabs.com
http://dx.doi.org/10.1016/j.cell.2014.08.020
The 2014 LaskerKoshland Special Achievement Award will be presented to Mary-Claire King,
a pioneer and visionary who revolutionized the use of genetics to identify disease genes, provide
insights into human evolution, and champion human rights causes.Progress in scientific understanding is not
a continuous process. From time to time,
a great idea (along with the evidence for
it) provides an essential new perspective
that opens new possibilities not envi-
sioned before. In our time, the great
idea that transformed understanding of
biology is, of course, the central role of
DNA as the repository and carrier of bio-
logical information from generation to
generation. Once it became clear that ge-
netic information is encoded as molecular
sequences of nucleotides in the DNA that
are translated into sequences of amino
acid sequences in the proteins, it became
possible to explain all of the fundamental
elements of genetics and evolution in
terms of molecular sequence. Moreover,
much of the basic biology of health and
disease could be understood better in
the light of the flow of information from
the genome to phenotype. The great
idea that biology is about information
and DNA, and that protein sequences
were the nexus of this information was
the work of a relatively few pioneers in
the field now referred to as ‘‘molecular
biology,’’ of whom Francis Crick and
James Watson are by far the best known.
The latter half of the 20th century saw
the penetration of the ideas around DNA
and molecular sequences into all areas
of biology. Very many scientists partici-
pated inwhat became relatively organized
world-wide efforts to exploit molecular
sequences. Most prominent among these
was the concerted effort to determine the
DNA sequence of human genomes and
ultimately the genomes of the many other
organisms on our planet. Another major
effort was to determine and catalog the
molecular sequence changes that result
in human diseases, ranging from the rare
inherited Mendelian traits (e.g., cystic
fibrosis) to the all-too-common diseases1230 Cell 158, September 11, 2014 ª2014 Ellike diabetes, cancer, and Alzheimer dis-
ease that appear to have a number of etio-
logic determinants, some inherited and
some not. A third major effort was the
exploitation of molecular sequence dif-
ferences to understand evolution once
it became clear that molecular sequence
divergence is a logical and effective
metric for measuring evolutionary dis-
tance. Finally, molecular sequence identi-
ties became the standard for forensic
identification of individuals. Huge data-
bases of such sequences are maintained
and used by police andmilitary authorities
around the globe. Each of these efforts
necessarily became associated with ‘‘big
science.’’ Papers in the literature today
typically feature not a handful but hun-
dreds of authors.
However, a closer reading of the history
will show that many of the key insights
that fueled the progress that justified
the ‘‘big science’’ efforts continued to
be made by scientists working in the
traditional academic way. Indeed, it
seems that the flow of these ideas re-
mains essential to making the ‘‘big sci-
ence’’ productive.
Mary-Claire King, American Cancer
Society Professor in the Departments of
Medicine and Genome Sciences at the
University of Washington, Seattle, who
will be honored with the 2014 Lasker
Koshland Special Achievement Award,
repeatedly contributed insights involving
molecular sequences and their uses.
Although some of her work directly re-
sulted in the large efforts cited above,
she herself worked with a small group,
only occasionally collaborating with
some of the ‘‘big science’’ efforts. Her
achievements had a transformational ef-
fect on the fields of molecular evolution,
the genetics of breast cancer suscep-
tibility in humans, and the use of DNAsevier Inc.sequence similarity forensically to identify
individuals. These achievements form the
basis for the LaskerKoshland Special
Achievement Award.
One hallmark of Dr. King’s work is
thorough mathematical and statistical
analysis. Mathematics was Dr. King’s
undergraduate major; quantitative anal-
ysis was often critical to her success.
Another hallmark of her work is intellectual
courage. Each of her major successes
was undertaken against the odds—often
long odds. Finally, Dr. King is notable for
her determination to find ways to apply
her scientific knowledge and abilities
for the greater good of society wherever
possible.
Humans, Chimpanzees, Molecular
Sequences, and Evolutionary
Metrics
Until the DNA era, the mechanism
of evolutionary change was not acces-
sible for serious study. Before 1950, there
was not even a consensus on the chemi-
cal nature of genes. Molecular sequences
changed all of that. In 1951, Fred Sanger
determined the amino acid sequence
of the B chain of bovine insulin (Sanger
and Tuppy, 1951). Soon thereafter, in
1956, Vernon Ingram discovered the
single amino acid sequence change in hu-
man b-hemoglobin that causes sickle cell
disease (Ingram, 1956). Many determina-
tions of amino acid sequences, as well
as the occasional mutants or polymor-
phisms in them, soon followed. These
developments were accompanied by
development of methods for assessing
protein polymorphism by immunological
and physical means as well.
In her doctoral dissertation with the late
Allan Wilson, Mary-Claire King undertook
‘‘.to obtain a quantitative and objec-
tive estimate of the ‘genetic distance’
Mapping of a causative gene of familial
cancer, later identified as BRCA1, on the
long arm of chromosome 17. Image from
Hall et al. (1990).between species.’’ Her results, published
in a nine-page lead article in Sci-
ence magazine (King and Wilson, 1975),
assembled protein sequence and poly-
morphism data and analyzed them sta-
tistically to obtain an estimate of amino
acid sequence divergence between
human and chimpanzee. The result was
striking: all of the methods that they
used (including nucleic acid hybridization,
which had just been introduced) agreed
that the degree of difference in sequence
at the protein level is about 1%. This de-
gree of difference was inconsistent with
the notion that the biological differences
between the two species could be ac-
counted for by protein differences.
Instead, King and Wilson suggested that
the differences were due to a ‘‘.relatively
small number of genetic changes in
systems controlling the expression of
genes..’’
The extreme similarity of the chim-
panzee and human molecular sequences
was fully validated 30 years later by com-
parison of the full genomic sequences
of the two species. The King and Wilson
regulatory hypothesis is still, after all this
time, the best explanation for themanifest
differences in biological properties. Most
significantly, the use of molecular se-
quences as the ‘‘quantitative and objec-
tive estimate’’ for evolutionary distance
has become universally accepted.Breast Cancer and the Genetics of
Common Complex Diseases
Mary-Claire King began her studies of
breast cancer families in 1974, shortly af-
ter finishing her Ph.D. She undertook to
find genes that predispose to breast can-
cer even though there was no known
method by which such a thing could be
done. She began by searching for families
in which a simple Mendelian pattern of
inheritance could have caused the dis-
ease phenotype. She carried out a thor-
ough segregation analysis that gave a
maximum likelihood estimate that 4% of
the thousands of families in a national
cancer registry were segregating a highly
penetrant autosomal-dominant gene that
increased the risk of breast cancer about
10-fold by age 70 (Newman et al., 1988).
It was not until 1980 that human gene
mapping became practical (Botstein
et al., 1980). Then it was realized that
DNA polymorphisms could be used as
genetic markers and followed in studies
of families for linkage between the DNA
marker and a simply inherited Mendelian
disease. It was not at all clear, however,
how linkage mapping might contribute
if the genetic determinants were more
complicated than simple Mendelian. For
example, if there are in the population
several Mendelian loci conferring the
same phenotype but unlinked to one
another (i.e., locus heterogeneity), the
mapping would quickly become difficult.
Moreover, if in addition there were non-
genetic causes for the same disease
phenotype, the statistical signal for link-
age might drown in the noise of larger
numbers of nongenetic cases.
Undaunted, Dr. King went forward with
linkage analysis in 23 families that she
identified as most likely to be segregating
an autosomal-dominant gene predispos-
ing to breast cancer. She adopted the
laboriousmethods introduced in 1980: re-
striction fragment length polymorphisms
assessed by hybridization with radio-
active probes on Southern blots. She
applied a statistical test for heterogeneity
that indicated that the 23 families were not
all segregating the same gene. Facedwith
this heterogeneity, she had an insight: the
families displaying early-onset disease
might represent a more homogeneous
cause. This turned out to be the key to
success. It is important to note that sort-
ing the families before linkage analysisCell 158, Sepwas key: by taking age of onset as a prior
condition, she avoided the necessity to
make corrections for multiple hypothesis
testing that would have vitiated the statis-
tical significance of the finding.
Thus, Dr. King was able to use her
insight and her command of the relevant
statistical theory to separate signal from
noise in the linkage data in a rigorous
and robust way, resulting in the unambig-
uous mapping of a causative gene to the
long arm of human chromosome 17. As
can be seen from Figure 3 of her Science
paper (Hall et al., 1990), the cumulative
LOD score (which is a measure of the
evidence of linkage) is dependent on the
age of onset of breast cancer. The gene
evidently is the major cause of cancer in
only those families that display the early
age of onset; the statistic becomes nega-
tive (meaning no support for linkage) for
those families with older ages of onset.
The finding of the gene on chromosome
17q21 (which she named BRCA1) is the
first example of detection and linkage
mapping of severe mutations in com-
mon complex diseases. Dr. King’s work
became the model for this approach and
for how the issues of multiple-hypothesis
testing (the bane of ‘‘big data’’ analysis)
can be overcome by a judicious choice
of prior hypothesis.
Although the BRCA1 gene ultimately
was cloned and sequenced by others,
King’s group continued their family
studies. In 1994 they reported nine
different BRCA1 germline mutations in
ten extended families, confirming the
identity ofBRCA1 as the gene on chromo-
some 17q21 that predisposes to breast
and ovarian cancer. By 1998, her group,
among others, had found that BRCA1
actually accounts for only a few percent
of all breast cancer, as predicted by her
mathematical work a decade earlier,
forcefully illustrating that the original suc-
cess had depended upon King’s decision
to focus on only those families displaying
early-onset disease. Six of the early-onset
families segregate BRCA1, and the sev-
enth segregates another gene now called
BRCA2. The genes segregating in half of
the remaining families have been found;
the other half remain unknown.
Dr. King’s work has made it possible
to design diagnostic tests that today are
in routine clinical practice. Women who
carry BRCA1 mutations carry a roughlytember 11, 2014 ª2014 Elsevier Inc. 1231
10-fold elevated risk of breast or ovarian
cancer and are examined more frequently
for early signs of tumors. Many elect to
undergo prophylactic salpingo-oopho-
rectomy (removal of the fallopian tubes
and ovaries) and/or prophylactic mastec-
tomy, which for these women can be life-
saving. Dr. King’s discovery of BRCA1
led the way to linkage studies of similar
design that resulted in the finding of genes
predisposing to many other kinds of
cancer, notably colon cancer. Diagnostic
methods that detect these alleles have
also become routine in medical practice,
and thousands of patients benefit.
Dr. King’s focus on early-onset families
provided a paradigm for finding genes
underlying common complex diseases,
namely to focus on the families with the
most severe phenotypes. This paradigm
has resulted in the discovery of genes
predisposing to Alzheimer disease, coro-
nary artery disease, and Parkinson’s dis-
ease, among many others. As was the
case for breast cancer, these discoveries
help people in two ways: better under-
standing of the disease biology and bet-
ter information for the treatment of the
affected.
Mitochondrial DNA, Grandmothers,
and Human Rights
In the time of the notorious Argentinian
dictatorship of 1975–1983, the Grand-
mothers of the Plaza de Mayo organized
themselves in protest of the systematic
murders of political opponents of the
regime and their families. In addition to
their justly famous demonstrations at the
Plaza, they organized searches for the
missing children of the ‘‘disappeared,’’ in-
fants whom they had learned had been
spared death but were instead distributed
to unrelated families, often families of
police or military complicit in the mur-
ders. After 1983, when redress became
possible, at least in principle, what
the Grandmothers most lacked was a
convincing way to prove the identities of
children once they found them. They un-
derstood enough genetics to intuit that
there must be a way to do this by some
kind of blood test. They searched out
experts—first in Latin America and then,
as their fame grew, worldwide.
The Grandmothers were referred to
Mary-Claire King, initially as an authority
who might be able to provide the robust1232 Cell 158, September 11, 2014 ª2014 Elstatistical methods that could convince
a court. At the time, the technology avail-
able was blood groups and histocompat-
ibility markers. Dr. King quickly realized
that, although the theoretical issues
were easily solved, the actual determina-
tion required fresh blood and specific
perishable immunological reagents. The
Grandmothers, ever undaunted, identi-
fied a suitable laboratory in Buenos Aires,
and Dr. King became the analyst for
the first cases in which kidnapped chil-
dren were identified and returned to their
proper families by the courts.
The great step forward in solving
the grandchildren’s identification problem
came when Dr. King found a way to apply
direct DNA sequencing to it. The poly-
merase chain reaction (PCR) had recently
been developed (but not yet commercial-
ized), and Dr. King knew that there might
be more than enough polymorphism in
human mitochondrial DNA to serve for
statistically secure identification. It soon
became clear that this was a perfect
solution, both theoretically and techni-
cally. Mitochondrial DNA is inherited
strictly along the maternal lineage. All
of the children of a given mother have
identical copies of the mitochondrial
DNA sequence, the mother has the
same sequence as her mother, and so
on. Further, any other relative from the
maternal line will also have the samemito-
chondrial DNA sequence, so it is easy to
find samples from a family for comparison
even when the parents and grandparents
are unavailable. Mitochondrial DNA is
abundant in tissues, very hardy because
of its small size, and readily amplified
by PCR.
In this way, Dr. King became the tech-
nology leader in identification of human
tissue. She pioneered the technology for
extracting mitochondrial DNA from teeth,
often the last intact tissues available for
testing (Ginther et al., 1992). The technol-
ogy she developed for the Grandmothers
of the Plaza de Mayo has come into gen-
eral use by forensic scientists around
the world. Dr. King gave the world the
ability to securely identify victims of natu-
ral disaster, crime, and war, as well as
kidnapping and political murder. Millions
today know the fates of their loved ones
because of this technology.
Dr. King’s remarkable devotion to hu-
man genetics on the one hand and humansevier Inc.rights on the other has continued to this
day. For about the last 20 years, she has
identified numerous genes that cause
inherited hearing loss. She has done this
as a part of a remarkable collabora-
tion between Israeli and Palestinian
geneticists. They study consanguineous
families in which the probability of the
emergence of a recessive trait is very
high because of the inheritance of the
same stretch of DNA from both parents.
Such families are abundant in both Israel
and Palestine. This collaboration, which
has continued for decades, led to a joint
PhD program between Bethlehem and
Tel Aviv Universities.
Today, Dr. King is focused on the
genetic and genomic analysis of another
complex disease, schizophrenia. With
her usual spirit of proceeding against the
long odds, she has used genomic tech-
nology to show that (1) people with this
disease are enriched for large deletions
and duplications that appear to involve
genes known to function in neurological
development and (2) schizophrenic indi-
viduals often contain de novo muta-
tions that disrupt genes with neurological
functions.
To conclude, Dr. Mary-Claire King
has provided creative scientific ad-
vances, both theoretical and practical, to
the development of human molecular ge-
netics from its earliest beginnings in the
pre-DNA sequence era to the current
day of large-scale genomics. In all of her
work, she has focused not only on the
science, but also on the people who
benefit. It is entirely fitting that this exem-
plary scientist and citizen of the world be
awarded the LaskerKoshland Special
Achievement Award.
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